U.K. Catalyst fund injects $70M into new generation of biotechs bit.ly/Zf7PzW #VC #biotech

First in class moab #pancreatic #cancer with In vivo Poc under hunanization ready for licence, further info Wed, PR.30 #bes13

Press release #lavanguardia #bes13 yfrog.com/khcbtmcrj

2nd day promoting the BioRegion of Catalonia at BIO-Europe Spring Barcelona. Biocat booth (number 25) #BES13: flic.kr/p/e2DGMj

Come to the Lykera’s company presentation today at 10:30 AM, room 118, Level 1 lykerabiomed.com #cancer #reasearch #BES13

Lykera Biomed's F. Mitjans explains types of potential collaborations for company's compounds, including LK1-S100A4 and LK3-S100P. #BES13

More than 2,000 top executives visit #BES13 in Barcelona : biocat.cat/en/news/more-2…

Pancreatic #cancer treatment from Lykera Biomed, ready for regulatory preclinical phase: biocat.cat/en/news/pancre…

FDA Accelerated Approval of Oncology Drugs hub.am/XX4Drz Overnight success and regulatory pathways.

Ten companies seek capital at 10th #Healthcare #Barcelona Investment Forum MIHealth Forum: biocat.cat/en/news/ten-co…

Lykera Biomed, tractament càncer per cèl•lules de l’estroma del tumor i angiogènesi bit.ly/139x7Fe #forumhealthcare #biotecnologia

New Annual Report is now available.See the work our sectors having been doing to raise the profile of EU biotech:bit.ly/10nmkoi

Original paper on anti-#CD47 #antibody #cancer #research goo.gl/JjgLe #pnas

Nanoparticle clearance governed by Th1/Th2 immunity and strain background goo.gl/yhTq3 #nanotechnology #research #jci #nanomed

#JCINL Daily is out! paper.li/JCINederland/1… ▸ Top stories today via @jciprograms Lykera Biomed

PT News: B-MS signs up Samsung to make Yervoy dlvr.it/3kMn2x #pharmaceuticals

Therapeutic Targeting of Tumor Growth and #Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody #PlosOne #cancer goo.gl/efbDS4

What's the State of Cancer Care in America? In 10 mins, join our live stream bit.ly/1gnoHeO #CancerCareAmerica

Ahead of Print: Primary Mesenchymal Tumors of the Pancreas: Single-Center Experience Over 16 Years: Objective:... bit.ly/1kEWPZd